Deep Brain Stimulation for Treatment Resistant Depression
Not Applicable
Recruiting
- Conditions
- Depressive Disorder, Major
- Registration Number
- NCT05716555
- Lead Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Brief Summary
This study will investigate the safety and efficacy of deep brain stimulation (DBS) in lateral habenula (LH) for patients with treatment-resistant depression.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 2
Inclusion Criteria
- Age 18-70, regardless of gender;
- Diagnostic And Statistical Manual Of Mental Disorders 5th Ed (DSM-V), for Psychiatrists' Examination of Severe Depressive Disorders;
- Same diagnostic conclusions based on DSM-V made by two independent psychiatrists;
- A minimum of 24 months of depressive history, over 2 or more adequate antidepressant trials with Hamilton Depression Rating Scale (HAMD) reduction rate ≤20% (including MECT) ;
- HAMD-17 scores ⩾ 20 at screening;
- Functional General Assessment Table (GAF) rating ≤50;
- Able to comply with the operational and administrative requirements of participation in the study, and able to give written informed consent.
Exclusion Criteria
- Patients with severe or unstable mental, liver, kidney, endocrine, hematological diseases, or those with psychotic co-morbidities, including personality disorders;
- History of substance abuse in the past 12 months; history of epilepsy, or febrile seizure in childhood;
- Patients who have attempted suicide within the past 6 months, or have had a secondary suicide attempt within the past 2 years;
- Women who are breastfeeding, pregnant, or intend to be pregnant during the clinical study;
- Any surgical contraindications to undergoing deep brain stimulation (DBS);
- Patients who cannot give full informed consent.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Hamilton Depression Rating Scale 52 weeks after surgery Change in Hamilton Depression Rating Scale score from baseline to 52 weeks after surgery
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways in the lateral habenula are modulated by DBS to alleviate treatment-resistant depression?
How does LH DBS compare to transcranial magnetic stimulation (TMS) in efficacy for treatment-resistant depression?
Which neuroimaging biomarkers predict response to lateral habenula DBS in major depressive disorder patients?
What are the safety profiles and management strategies for adverse events in LH DBS for depression?
Are there pharmacological agents that synergize with lateral habenula DBS in treating treatment-resistant depression?
Trial Locations
- Locations (1)
Zhejiang University School of Medicine Second Affiliated Hospital
🇨🇳Hangzhou, Zhejiang, China
Zhejiang University School of Medicine Second Affiliated Hospital🇨🇳Hangzhou, Zhejiang, ChinaHemmings Wu, MD, PhDContact+86-571-87784716hemmings@zju.edu.cn